Jpmorgan Chase & CO Cel Sci Corp Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Cel Sci Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,661 shares of CVM stock, worth $6,253. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,661
Previous 10,449
74.53%
Holding current value
$6,253
Previous $4,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CVM
# of Institutions
65Shares Held
7.55MCall Options Held
73.8KPut Options Held
106K-
Vanguard Group Inc Valley Forge, PA2.35MShares$5.53 Million0.0% of portfolio
-
Gwn Securities Inc. Palm Beach Gardens, FL1.19MShares$2.8 Million0.02% of portfolio
-
Black Rock Inc. New York, NY775KShares$1.82 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA753KShares$1.77 Million0.0% of portfolio
-
Mai Capital Management526KShares$1.24 Million0.0% of portfolio
About CEL SCI CORP
- Ticker CVM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,367,500
- Market Cap $102M
- Description
- CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...